Precision Biosciences (DTIL) Research & Development (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Research & Development of $13.1 million for Q1 2026, down 3.52% year-over-year from $13.6 million in Q1 2025, and down 9.36% quarter-over-quarter from $14.5 million in Q4 2025.
Precision Biosciences (DTIL) Research & Development (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Research & Development for 9 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 3.52% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $53.7 million (down 10.22% YoY), while the FY2025 annual figure was $54.2 million, down 9.04% from the prior year.
- Research & Development retreated to $13.1 million in Q1 2026 per DTIL's latest filing, from $14.5 million in the prior quarter.
- Across five years, Research & Development topped out at $22.9 million in Q2 2022 and bottomed at $11.0 million in Q1 2023.
- Historically, Research & Development has averaged $14.6 million across 5 years, with a median of $13.4 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development sank 54.67% — and 2023, when it jumped 34.8%.
- Precision Biosciences' Research & Development stood at $12.7 million in 2022, then rose by 5.57% to $13.4 million in 2023, then rose by 18.81% to $15.9 million in 2024, then retreated by 9.07% to $14.5 million in 2025, then retreated by 9.36% to $13.1 million in 2026.
- Business Quant data shows DTIL's Research & Development at $13.1 million in Q1 2026, $14.5 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 97.90 Mn |
| 10 | Precision Biosciences | 224.69 Mn | 137.15 Mn | - | 12.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.39 Mn |
| Mar 31, 2026 | 13.11 Mn |
| Dec 31, 2025 | 14.46 Mn |
| Sep 30, 2025 | 13.35 Mn |
| Jun 30, 2025 | 12.77 Mn |
| Mar 31, 2025 | 13.59 Mn |
| Dec 31, 2024 | 15.91 Mn |
| Sep 30, 2024 | 13.08 Mn |
| Jun 30, 2024 | 17.23 Mn |
| Mar 31, 2024 | 13.34 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | 15.85 Mn |
| Jun 30, 2023 | 13.09 Mn |
| Mar 31, 2023 | 11.05 Mn |
| Dec 31, 2022 | 12.68 Mn |
| Sep 30, 2022 | 11.76 Mn |
| Jun 30, 2022 | 22.94 Mn |
| Mar 31, 2022 | 19.97 Mn |
| Dec 31, 2021 | 26.47 Mn |
| Sep 30, 2021 | 25.94 Mn |